Table 1.
Baseline (MAPT Study Year 1 visit) characteristics of the sample
| Parameters | n | Value* |
|---|---|---|
| Age, y | 168 | 76 (73–79) |
| Women, No. (%) | 168 | 129 (77) |
| MAPT group allocation, No. (%) | ||
| Omega 3 + MDI group | 168 | 40 (24) |
| Omega 3 group | 168 | 40 (24) |
| MDI group | 168 | 45 (27) |
| Control group | 168 | 43 (26) |
| Body Mass Index | 168 | 26.3 (22.6–28.8) |
| Moderate and vigorous physical activity (MET-mins/week) | 168 | 804 (315–1492) |
| Grip strength (kg) | 168 | 25.0 (21.0–31.0) |
| Appendicular lean mass (kg) | 168 | 17.4 (15.2–20.8) |
| Gait speed (m/s) | 154 | 1.08 (0.93–1.18) |
| Apelin (pg/ml) | 126 | 1617.0 (987.9–2413.4) |
| GDF15 (pg/ml) | 148 | 983.5 (761.0–1279.5) |
| IL6 (pg/ml) | 148 | 2.38 (1.65–3.82) |
*Median (interquartile range) for continuous variables; count (percentage) for categorical variables; Abbreviations: GDF-15= Growth Differentiating Factor-15; IL-6= interleukin 6; MAPT=Multidomain Alzheimer Preventive Trial; MDI= Multi-Domain Intervention.